Lymphoma

2023 - 2 - 27

CDX-1140 by Celldex Therapeutics for Lymphoma: Likelihood of ... (pharmaceutical-technology.com)

CDX-1140is under clinical development by Celldex Therapeutics and currently in Phase I for Lymphoma.

Celldex Therapeutics (Celldex) is a bio-pharmaceutical company that discovers, develops, and commercializes targeted immunotherapy and other biologics for the treatment of various types of cancers. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. GlobalData’s report assesses how CDX-1140’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

CCAR-039 by Cellular Biomedicine Group for Follicular Lymphoma ... (pharmaceutical-technology.com)

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug ...

It was under development for the treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL) and relapsed or refractory B-cell non-Hodgkin lymphoma. CCAR-039 is under development for the treatment of non-Hodgkin's lymphoma (NHL), mantle cell lymphoma, diffuse large B-cell lymphoma and follicular lymphoma. GlobalData’s report assesses how CCAR-039’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Post cover
Image courtesy of "Cornell Chronicle"

Weill Cornell Medicine awarded grant for lymphoma research ... (Cornell Chronicle)

Weill Cornell Medicine has been awarded a five-year, $4.2 million grant by the National Cancer Institute to investigate the molecular mechanisms by which ...

The proposed projects build on research using CRISPR and chemical genetic analysis that was conducted by the lab of co-PI Dr. With the current grant, Cesarman and co-PI Dr. “You can think of infection by Epstein-Barr Virus as being an opportunistic cause of cancer,” Cesarman said. In EBV-associated cancers, the amount and type of viral proteins made are variable, and affect how the immune system recognizes the infected tumor cells. However, through a poorly understood mechanism, the virus can begin making additional viral proteins that can induce cancers, including diffuse large B cell lymphoma, a type of blood cancer. The funding will support projects that began with a grant awarded by the

Explore the last week